Literature DB >> 24307198

Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.

Patrick Thurner1, Anna Stary-Weinzinger, Hend Gafar, Vaibhavkumar S Gawali, Oliver Kudlacek, Juergen Zezula, Karlheinz Hilber, Stefan Boehm, Walter Sandtner, Xaver Koenig.   

Abstract

Ibogaine is a psychoactive indole alkaloid. Its use as an antiaddictive agent has been accompanied by QT prolongation and cardiac arrhythmias, which are most likely caused by human ether a go-go-related gene (hERG) potassium channel inhibition. Therefore, we studied in detail the interaction of ibogaine with hERG channels heterologously expressed in mammalian kidney tsA-201 cells. Currents through hERG channels were blocked regardless of whether ibogaine was applied via the extracellular or intracellular solution. The extent of inhibition was determined by the relative pH values. Block occurred during activation of the channels and was not observed for resting channels. With increasing depolarizations, ibogaine block grew and developed faster. Steady-state activation and inactivation of the channel were shifted to more negative potentials. Deactivation was slowed, whereas inactivation was accelerated. Mutations in the binding site reported for other hERG channel blockers (Y652A and F656A) reduced the potency of ibogaine, whereas an inactivation-deficient double mutant (G628C/S631C) was as sensitive as wild-type channels. Molecular drug docking indicated binding within the inner cavity of the channel independently of the protonation of ibogaine. Experimental current traces were fit to a kinetic model of hERG channel gating, revealing preferential binding of ibogaine to the open and inactivated state. Taken together, these findings show that ibogaine blocks hERG channels from the cytosolic side either in its charged form alone or in company with its uncharged form and alters the currents by changing the relative contribution of channel states over time.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24307198     DOI: 10.1124/jpet.113.209643

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  8 in total

1.  Identification of a novel putative inhibitor of the Plasmodium falciparum purine nucleoside phosphorylase: exploring the purine salvage pathway to design new antimalarial drugs.

Authors:  Luciano Porto Kagami; Gustavo Machado das Neves; Ricardo Pereira Rodrigues; Vinicius Barreto da Silva; Vera Lucia Eifler-Lima; Daniel Fábio Kawano
Journal:  Mol Divers       Date:  2017-05-18       Impact factor: 2.943

Review 2.  A Pharmacological Perspective on Plant-derived Bioactive Molecules for Epilepsy.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Jesús Herrera-Bravo; Miquel Martorell; Farukh Sharopov; Tugba Boyunegmez Tumer; Begum Kurt; Chintha Lankatillake; Anca Oana Docea; Ana Catarina Moreira; Daniel A Dias; Mohamad Fawzi Mahomoodally; Devina Lobine; Natália Cruz-Martins; Manoj Kumar; Daniela Calina
Journal:  Neurochem Res       Date:  2021-06-12       Impact factor: 3.996

3.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256

Review 4.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

Review 5.  The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation.

Authors:  Barbara Wiśniowska; Sebastian Polak
Journal:  Curr Pharmacol Rep       Date:  2016-10-27

6.  A non-hallucinogenic psychedelic analogue with therapeutic potential.

Authors:  Lindsay P Cameron; Robert J Tombari; Ju Lu; Alexander J Pell; Zefan Q Hurley; Yann Ehinger; Maxemiliano V Vargas; Matthew N McCarroll; Jack C Taylor; Douglas Myers-Turnbull; Taohui Liu; Bianca Yaghoobi; Lauren J Laskowski; Emilie I Anderson; Guoliang Zhang; Jayashri Viswanathan; Brandon M Brown; Michelle Tjia; Lee E Dunlap; Zachary T Rabow; Oliver Fiehn; Heike Wulff; John D McCorvy; Pamela J Lein; David Kokel; Dorit Ron; Jamie Peters; Yi Zuo; David E Olson
Journal:  Nature       Date:  2020-12-09       Impact factor: 49.962

Review 7.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

8.  Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Lena Rubi; Daniel Eckert; Stefan Boehm; Karlheinz Hilber; Xaver Koenig
Journal:  Cardiovasc Toxicol       Date:  2017-04       Impact factor: 3.231

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.